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UNCONVENTIONAL GENE BEHAVIOR AND
ITS RELATIONSHIP TO PSEUDOGENES
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CHICAGO, IL 60631, USA

Proving that a gene unit is totally nonfunctional, and is therefore definitely a pseudogene,
is impossible.
Mounsey et. al. [49, p. 772]
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ABSTRACT
Traditionally, pseudogenes have been regarded as “dead” gene copies as a result of features such as
the absence of promoters and the existence of premature stop codons. However, the recognition of a
truly disabled gene is not as straightforward as once believed. It is now known that promoters may be
cryptic. Genomic recoding processes can allow for the synthesis of a peptide despite the present of
premature stop codons. Alternative splicing can allow for the omission of exons that contain premature
stop codons. Finally, negative evidence for pseudogene expression, for the relatively few pseudogenes
for which it is available, must be interpreted with caution. This is in view of the fact that many genes
express themselves only under very restricted conditions.
INTRODUCTION
Each component of the eukaryotic gene plays a role in its expression. The DNA sequence of the gene
that is transcribed into mRNA and then translated into a protein (in the case of protein-coding genes) is
called the open reading frame. The promoter indicates the approximate location where transcription is to
begin while the polyadenylation signal terminates the transcription. Some genes have both exons and
introns, and these are marked off by splice sites. The primary RNA transcript includes both exons and
introns, but the latter are spliced out in the mature mRNA. A translation initiation codon signals the
location where the mature mRNA is to be translated into a peptide, while the stop codon terminates the
translation process.
In many genes, features such as the promoter and initiation codons can be recognized solely by
inspection of the gene’s DNA sequence, and gene-search computer algorithms have been designed and
used to exploit this fact. However, it is commonly acknowledged that an unknown fraction of genes is
missed by such algorithms as a result of unconventional genes whose sequences deviate in some
important-but presently unknown-way from canonical genes. Such genes can only be discovered
through traditional genetics or biochemistry.
Three decades ago, Susumu Ohno, a prominent Japanese geneticist, suggested that noncoding DNA
lacks function, and originates from the remnants of dysfunctional genes. In fact, by analogy to the fossils
found in the Earth’s crust, he called them fossilized genes [51, 37]. In time, “dead” gene copies came to
be called pseudogenes. They clearly resemble specific genes but seem to be disabled as a result of
inferred mutational lesions:
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Almost any imaginable defect can be found in pseudogenes, including abnormal initiation
and termination codons, altered normally invariant codons, deletons, insertions, and
nonsense mutations, as well as defects in promoter, RNA splicing, and polyadenylation
sequences. [33, p. 253]
Pseudogenes are often more dissimilar from their certainly functional paralogs than the latter are from
each other. This sequence diversity is interpreted as indicative of the fact that purifying selection is not
acting to eliminate mutations from these putatively untranscribed gene-like sequences. Finally,
pseudogenes at first were not observed to be transcribed nor translated in standard cell biology assays.
All of this led to the belief that they are simply disabled copies of genes.
This thinking was perhaps reasonable some twenty years ago. However, advances in genomic
knowledge now complicate the identification of pseudogenes. Features such as genomic recoding,
alternative splicing, and cryptic promoters provide evidence that some apparent lesions, as occur in
pseudogenes, can be over-ridden. Moreover, this over-riding can be regulatory as well as reparative in
nature.
Pseudogenes have been exploited by opponents of special creation. The existence of seemingly
disabled gene copies, notably in human genomes, have been taken as evidence against the design of
genomes by a Designer. In addition, some of the apparent disablements found in pseudogenes have
been found to be shared by humans and apes, prompting the argument that only shared common
descent could account for these “shared mistakes” [43]. There is no shortage of anti-creationists who
have repeated this assertion. However, the “shared mistake” argument is a dubious one. It ignores or
belittles the fact that pseudogenes can acquire identical “lesions” independently [70]. If it turns out that
pseudogenes are not disabled genes after all, the “shared mistake” argument would become all but
moot.
Owing to the breadth of this topic, a series of papers is planned which address pseudogene-related
phenomena. There are two main types of pseudogenes: classical and processed (the latter also called
retropseudogenes). Interpersed repeats, considered by some to be retropseudogenes, are not
discussed in this work. This paper emphasizes classical pseudogenes, although most of the discussion
is also applicable to retropseudogenes. Consideration of pseudogene features themselves is limited to
absent or disabled promoters, and to premature stop codons. Throughout this work, the emphasis is on
eukaryotic genomes, and on the similarities which they share. In fact, in this regard, Resnick and Cox
[55], in all seriousness, call yeast an honorary mammal.
DIVERSITY OF PROMOTERS PREVENTS READY IDENTIFICATION
Early studies of genes had indicated that certain conserved sequences are responsible for transcription.
Because such regulatory sequences can be experimentally inactivated by artificial mutation, it is
commonly assumed that inferred natural mutations of regulatory sequences will have an identical effect,
transcriptionally silencing an otherwise active gene. However, even an obvious alteration of normally
conserved gene transcription elements does not necessarily imply their inactivation. The γ-globin tarsier
pseudogene was once “pronounced dead” solely because the distal CCAAT box was missing, and the
second one had an ostensibly inactivating mutation (CcgAT). Now the γ-globin pseudogene is believed
to be functional based on the absence of nonsynonymous substitutions in the coding regions [44],
although the role of this sequence needs to be clarified.
The foregoing discussion is especially applicable to promoters, which are at the very core of the
transcription process. A functional promoter is required for transcription of a gene to begin. Inferences
are commonly made about the putative mutational inactivation of promoters in classical pseudogenes
and the absence of promoters in retropseudogenes. However, determining whether or not some kind of
functional promoter exists is no longer straightforward.
The most commonly occurring promoter complex includes the TATA box, which is usually situated about
30 nucleotides upstream of the translation start site (though it will still function as close as 15
nucleotides to the same: [52]). The TATA motif itself is an idealization, as it actually subsumes a large
diversity of AT-rich short sequences [5]. Moreover, the TATA box can turn up in unexpected locations,
even within the gene’s coding region [50].
We now realize that a variety of non-TATA sequences can function as promoters from the same 30
nucleotide distance [69]. Furthermore, in compositional contrast to the AT-rich TATA-type promoters,
GC-rich promoters also exist for a significant number of genes. They can be found embedded within
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CpG islands, occurring at variable distances from genes and sometimes even serving two genes
simultaneously [39]. It is significant that an increasing number of short nucleotide sequences are being
discovered that exhibit previously unsuspected promoter activity [59, 64]. These aptly named cryptic
promoters are more prevalent than previously supposed [75, p. 7373]. And, contrary to earlier beliefs,
neither the TBP nor the TFIID transcription factors need be present to bind to whatever promoter sites
there are in existence, as other TAFIIS can perform this role [68]. This further complicates our
understanding of promoter sequences.
Functional promoters can be difficult to identify because some of them regulate genes from a
considerable distance [63]. Moreover, some promoter sequences display little activity unless they work
together with enhancers. The latter, in turn, are especially difficult to identify because they are quite
variable in sequence and may be located at considerable distances from the promoter [28]. In fact,
enhancers and other gene regulatory elements that are situated hundreds of kilobases from the
promoter may be unexpectedly common [9].
It is a fairly common practice to compare pseudogenes with their gene paralogs, and then suspect that
the pseudogene is transcriptionally inert owing to the fact that its promoter region differs significantly
from that of its gene paralog, and the promoter is therefore presumably nonexistent or disabled.
However, it is certainly possible that an apparently retrotranscribed gene could be under the control of
an uncharacterized promoter. Such is the case for the human and rodent Supt4h and Supt4h2 genes,
prompting this comment:
This illustrates another potential complexity of the mammalian genome, i. e., the use of a
processed gene under the control of a different promoter region than the unspliced gene.
[7, p. 4960]
It is commonly supposed that, keeping in mind the usual loss of the promoter sequence during reverse
transcription, it is very unlikely that a retroposited gene sequence would fortuitously land near a suitable
pre-existing promoter. However, it is sobering to realize that, at least in yeast, 1% of randomly chosen
16bp DNA sequences can function as promoters at an equal or better rate than the canonical TATA box
[60]! And this does not consider weaker potential promoter sequences, at least some of which could
serve as promoters if they happen to be paired with suitable enhancers, which, as noted earlier, may
influence the promoter from a considerable distance.
Judgments about absent or damaged promoters must be re-examined in the light of the fact that
unexpectedly many genes have more than one promoter [1]. As an example, the experimental removal
of the entire 250 bp proximal promoter region (including the TATA box) of the human K18 gene fails to
silence the gene. It only causes the activation of a second (“Lazarus”) promoter [57]. The implication of
plural promoters for the avoidance of gene inactivation is recognized:
Alternatively, initiation of transcription at several sites, generating transcripts differing only
in their 5’-untranslated region, might render expression of the gene less vulnerable to
mutations in promoter sites. [1, p. 456]
The N-myc2 retrosequence in the woodchuck [16] constitutes a retropseudogene that is transcribed
thanks to a secondary promoter that had been unmasked by the reverse transcription process that
produced this retroposon. The transcriptional activity of the secondary promoter in N-myc2 is verified
experimentally. N-myc2 is transcribed in pathological tissue (liver tumors) as well as healthy tissue (the
brain). Owing to the fact that the N-myc2 sequence itself appears to be conserved, N-myc2 is suspected
of playing a biological role.
The Adh retrosequences in Drosophila provide an instructive example of the fact that the absence of a
functional promoter in a pseudogene is all but impossible to prove by examining the sequence:
We have gathered conflicting evidence about the putative functionality of these
retrosequences…Inspection of the 5’ region flanking the Adh retrosequences of the
obscura species did not show any remnant similar to the original promoter sequences or
structural homologies with an already-identified coding sequence. Nevertheless, we cannot
discard the idea that these retrosequences might have captured a new promoter and might
be transcribed. [41, p. 1323]
Since very few “promoter damaged” or “promoterless” pseudogenes have been experimentally
investigated for cryptic promotjjjer or secondary promoter activity, we cannot assume that they are
transcriptionally inert. Finally, it must be recognized that a significant number of pseudogenes have been
found to be transcriptionally active after all. However, “The functional relevance of pseudogene
transcripts remains unclear” [46, p. 112].
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INFERRING TRANSLATION-PREVENTING MUTATIONS
If a pseudogene can be transcribed, the next question concerns its capability for translation. Various
transcribed pseudogenes seem untranslatable because an initiator codon (usually AUG) is putatively
absent. However, some investigators [34] recognize the fact that the pseudogenes under study may in
fact be able to undergo translation initiation, and therefore potentially code a functional product, because
some alternative, downstream AUG codon can serve as the initiator. Moreover, analyses of alternative
splicing, a genomic process now known to be common [40], demonstrate that alternative AUG start
codons occur at a previously unsuspected high frequency in genes [47].
One form of splicing takes place in the bacterium Anaplasma phagocytophila. The p44-18 pseudogene
lacks an AUG start codon and is out of frame with its upstream overlapping paralogous gene, p44-1.
Thanks, however, to a splicing mechanism that excises the intervening sequence between p44-1 and
p44-18, the apparent impediments to pseudogene expression are overcome [76].
Assuming that translation initiation is possible, it is not straightforward to determine which alterations in
the ORF would necessarily prevent the completion of the translation process :
…it is likely that a substantial fraction of degenerative mutations (perhaps the majority) do
not lead to complete loss-of-function (subfunctionalization), …[42, p. 470]
As an example of this, Fletcer et. al. [15] are unsure whether they are dealing with a gene or a
pseudogene owing to the fact that, in spite of containing many inferred missense mutations, it may still
be capable of being translated into a variant but functional peptide. Similarly, Mezzina et . al. [45, p. 111]
raise the following caution about a transcribed rat pseudogene:
Nevertheless, we cannot rigorously exclude that the ΨmtTFA might have evolved to fulfill
some alternative function, in which case, the sequence drift could be ascribed to selection
for this alternative function rather to a lack of functionality.
This fact can be generalized. In his comprehensive survey of functional retrosequences (including
retropseudogenes), Brosius [4, p. 223] alludes to the ambiguity of mutational inactivation:
There are probably numerous additional retrogenes whose ORFs are not severely
compromised or could yield a truncated polypeptide, partially in a different reading frame
[Refs.]. However, transcription and/or translation are not documented. (emphasis added).
Even according to evolutionary long-age assumptions, a (pseudo)gene can be undergoing an
inferred rate of nonsynonymous to synonymous substitutions at a ratio approaching 1.0 without
necessarily being in a “mutational freefall”. For example, some erstwhile Drosophila pseudogenes
were subsequently promoted to at least potentially active gene status. The relatively large
inferred rates of nonsynonymous substitutions were reinterpreted as being the outcome of
selection pressure instead of the absence of functional constraints [53].
Many proteins contain certain domains or motifs deemed indispensable for the performance of
their biological roles. However, we now know that these may differ between paralogous genes, or
even between different splice variants from the same gene. Consider, for instance, the Bcl-rambo
gene, involved in proapoptotic activities, and which contains the BH1, BH2 and BH3 motifs. The
Bc1-rambo beta splice variant of the preceding, by contrast, lacks the foregoing domains and
translates into a BH4-only protein. An exonized Alu insertion, containing a premature stop codon,
is responsible for the synthesis of the domain-deprived shortened peptide [73]. Clearly, no
pseudogene should be reckoned “dead” just because its deduced peptide sequence lacks one or
more functional domains found in its gene paralogs. This fact can be extended to instances
where a missing-domain deduced peptide sequence fails to closely correspond to currently
known functional peptides:
If the transcript from 11Ψh-mtTFA was to be translated, it would produce a protein of 89
amino acids having 67.44% similarity with human mtTFA protein from amino acids 52-142,
thus lacking the second HGM box and subsequently the ability to bind DNA. A Blast
search against the SwissProt database has not revealed any other significant similarity,
suggesting that this putative protein, if present, could have a different role from h-mtTFA
[56. p. 231]
TRANSLATION IN THE CASE OF PARTIAL OPEN READING FRAMES
In genes exhibiting conventional behavior, the stop codon’s sole function is to give a signal for
translation of a peptide product to terminate. A nucleotide substitution may convert an amino acid coding
codon into a premature stop codon, or else an insertion or deletion may shift the open reading frame,
causing a premature stop codon to come into phase with the remaining ORF. This is commonly believed
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to indicate that any peptide, if synthesized at all, would be inert. Premature stop codons are
characteristic of pseudogenes [11, 19], so much so that they are employed to help identify them in the
genome [26].
There are several reasons, however, for no longer accepting the premature stop codon as an ipso facto
indicator of a pseudogene’s “dead” status. Numerous instances are now known where a truncated
peptide, far from being inert, exhibits much the same biological activity as its full-length isoform [42, 35,
36, 62, 66]. A premature stop codon may simply create two shorter ORFs, at least one of which may be
translated into a viable peptide, as is the case with a shortened Drosophila kelch protein that appears
sufficient for the insect’s development [58]. In their survey of the nematode worm's (C. elegans)
genome, Harrison et al. [23] point out that some of their so-designated pseudogenes may actually be
functional genes that make shortened peptides. Other investigators of pseudogenes [54] have voiced
similar concerns.
PREMATURE STOP CODONS SEEN IN A NEW LIGHT
Since, as noted earlier, the stop codon acts to terminate peptide synthesis, it seems self evident that a
premature stop codon necessarily indicates abnormal truncated translation. In striking opposition to this,
various cellular processes, collectively known as recoding, are now known (see Baranov et al. [2] for
review). Because recoding processes are known from taxonomically diverse groups, such as bacteria
and mammals, such processes may occur in many, if not most, groups. Without recoding, most of the
genes in question would not function properly, if at all, and would, by conventional definition, be
pseudogenes.
One notable recoding process is codon redefinition, which allows a certain codon to possess an
alternative mode of expression. Pointedly, codon redefinition allows for the premature stop codon to be
read-through so that the (pseud)ogene can complete the translation of a full-length peptide. Some forms
of readthrough are able to “over-rule” all three possible premature stop codons [62]. Those ORFs in
yeast genes that are subject to readthrough have explicitly been referred to as containing pseudogenic
features by Harrison et al. [25]. In certain yeast genes, readthrough of premature stop codons is said to
be fairly common [35]. Certain prions, responding to environmental stress, can activate a seeminglydisabled yeast (pseudo)gene by readthough of its premature stop codon:
Clearly, the lethal consequences of a nonsense mutation in an essential gene would be
overcome in an allosuppressor background. [PSI+] is an omnipotent allosuppressor
determinant, in that it enhances nonsense suppression of all three termination codons…
[10, p. 1978]
The foregoing example is recognized by Harrison and Gerstein [24] as a process for “resurrecting”
disabled genes. Other investigators [31, 32] are unsure whether they are dealing with a gene or a
pseudogene because of the recently appreciated ambiguity of the effects of premature stop codons.
In their investigation of pseudogenes in E. coli, Homma et al. [30] acknowledge the possibility of
recoding processes, but suggest that their (apparent) rarity makes them “…unlikely to be operative in
many of the pseudogene candidates:” However, sweeping generalizations about the rarity of recoding
processes may be unwarranted. Hammell et. al. [22] have found that 2.54% of yeast genes have the
distinctive heptamer sequence that is known to serve as a –1 ribosomal frameshift signal. Furthermore,
the apparent overall infrequency of recoding processes owes at least partly to research biases favoring
highly expressed, well-studied, canonically behaved genes [18]. Finally, we do not know the extent of
recoding processes in sporadically expressed genes, let alone supposed pseudogenes.
Some forms of translational readthrough are rather surprising. The premature stop codon is now known
to function as a “wild card” codon for specifying noncanonical amino acids, namely selenocysteine [29]
and possibly L-pyrrolysine [61]. The amino acid “alphabet” turns out to be larger than conventionally
believed. No one knows how many other rarely occurring amino acids are, or were, encoded by
otherwise pseudogenic premature stop codons.
Finally, even if all of the above-discussed factors are not applicable to a pseudogene with a premature
stop codon, this still does not guarantee its “dead” status, thanks to alternative splicing. Morgan et. al.
[48] have recently pointed out that this process has not been explored in detail even in certain highlyexpressed genes. Yousef et al. [74] caution that there may be functional splice variants of the human
siglec pseudogenes that are expressed only in certain tissues, certain developmental stages, or
pathological situations, or which can encode a truncated, yet functional peptide. This fact can now be
generalized. Thus, Harrison et al. [27] point out that it is now actually difficult to distinguish a functional
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gene from a nonprocessed pseudogene by inspection of the DNA sequence, all because an exon
containing a perceived disablement may be spliced out and the remaining transcript then translated into
a functional product.
ASSESSING THE EXPRESSION OF GENES AND PSEUDOGENES
Up to this point, discussion has been limited to the inference of potential pseudogene expression from
DNA sequence alone. It is clear that there are numerous difficulties in determining whether or not a
gene-like structure is biologically active. Consider, first of all, human genes in general:
Even with genome sequences in hand, our ability to identify genes is largely limited to
relatively large, evolutionarily conserved, moderately to highly expressed protein coding
genes. We know there are exceptions that fly below our radar—tiny genes, rapidly evolving
genes, genes expressed in only a few cells at special times—but we had hoped, with some
justification, that they aren’t too important or numerous [12, p. 137]
To the contrary, such rarely expressed genes may be numerous [14], and expressed only at low levels
[72, p. 811]. Large-scale surveys of mRNA sequences (EST libraries) have their own biases [40]. For
instance, they typically contain very few transcripts that have a low copy number or short half-life.
Pointedly, comparable characteristics may hold for most products of pseudogene expression. This
would especially include those situations where only a small part of the pseudogene’s sequence ever
becomes translated. Gene-search algorithms are particularly weak in this regard:
There exist two basic problems in gene recognition: recognition of protein coding regions
and recognition of the functional sites of genes. They are not yet satisfactorily solved,
especially in recognizing shorter coding regions of human genes…When sequences are
shortened, the difference of statistical characteristics between coding and noncoding
sequences tend to be small. [67, p. 207, 211]
As for pseudogene sequences themselves, there is no foolproof correlation between the number of
“disablements” in a pseudogene, and whether or not, at minimum, it turns out to be transcribed. Harrison
et al. [25] have found expressed ORFs in yeast genes in spite of these having at least five “lesions.” The
D2 pseudogene is transcribed in the ovary although it has seven lesions, excluding missense mutations
[8].
Having seen the inadequacy of inferential judgments of pseudogene viability, let us now consider actual
in vitro and in vivo experiments regarding the same. It turns out that many pseudogenes, inert according
to initial experiments, turn out to be transcribed after all [3]. Some are eventually found expressed only
in a few tissues [31, 32], including particular tissues in which other investigations had failed to detect any
expression [8, 13]. Various researchers [21, 46] caution that silence of a tested pseudogene may only
indicate that the minimal conditions for expression have not been met during the test. In like manner,
negative evidence of pseudogene translation can hardly be called conclusive. Note that any synthesized
peptide may degrade too rapidly for detection [20] and/or be translated in cell lines, tissues, or
developmental stages missed by experimental analyses [17].
It is an intriguing fact that, at least in the nematode C. elegans, genes involved in early development
have significantly more paralogous pseudogenes than those expressed in the later stages of the worm’s
life [6]. Might this imply at least a one-time expression of pseudogenes in the early development of an
organism? Pointedly, Fourel et al. [16] caution that their failure to observe the N-myc2 (pseudo)gene
expressing itself in fetal tissue does not exclude its potential expression in stem cell tissue. Owing to the
fact that only a vanishing number of pseudogenes have been tested for expression in stem cell tissue,
this takes on further significance.
CONCLUSIONS
Genes are much more complex than believed until recently, and we know much less about them than
we thought we did. Many genes do not behave in a straightforward, canonical manner. It is obvious that
the conventional gene/pseudogene demarcation is becoming more and more difficult to draw. More and
more (pseudo)genes with apparent lesions turn out to be transcribed and even translated. Sweeping
assertions about the nonfunctionality of pseudogenes [43] appear to be more and more dubious.
When pseudogenes are studied as a whole, it is almost always from the assumption of biological
inactivity and neutral molecular evolution [23]. Personal discussions with genomic specialists have
revealed the sobering fact that no one has examined pseudogenes for expression in a comprehensive
and systematic manner. All research is paradigm driven, and there is a disinclination to study objects
that are deemed relatively unimportant within the scope of the ruling paradigm. Add to this the fact that
the biotech industry prefers to allocate funding to the study of interesting genes in preference to the
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decoding of junk DNA [37, p. 1125]. It is time for pseudogenes to be systematically tested for biological
expression.
No attempt has been made in this paper to examine all pseudogene-related phenomena, nor to present
a scientific creationist hypothesis for their origin. However, the fact that some genes have apparent
lesions that actually serve regulatory purposes (as in recoding) allows one to consider at least some
pseudogenes as a type of highly-regulated noncanonical gene. These could have been specially created
with the pseudo-lesions serving as regulators of transcription and/or translation. Further creationist
research on pseudogenes should not only include systematic investigation of their expression, in all
tissues, but also of the relationship of pseudogenes to recoding processes. Studies should also be
undertaken on the potential function of pseudogenic transcripts and truncated proteins, both of which
have already been demonstrated to be functional in the case for two snail pseudogenes [71].
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